RNA Sequencing Analysis May Offer More Accurate Diagnosis for Common Pediatric Cancer
A pilot study proposes a promising clinically applicable genomic assay for the diagnosis of a heterogeneous pediatric leukemia.
A pilot study proposes a promising clinically applicable genomic assay for the diagnosis of a heterogeneous pediatric leukemia.
Alercell has launched a new website—Lena Diagnostics—dedicated to proprietary tests focused on early detection of cancer and leukemia.
Researchers have developed a new protocol for monitoring acute lymphoblastic leukemia to inform more effective treatment strategies.
The latest update is beneficial to researchers investigating myeloid disorders, and is now enabled with BCR-ABL fusion gene and KMT2A-PTD detection.
Read MoreBluestar Genomics’ technology can noninvasively detect cancers and help identify the underlying biology of the disease using epigenetic markers.
Read MoreThe panel has been tested to show excellent concordance with array data, and can detect both small and large CNVs, indels, LOH, and SNVs.
Read MoreSight Diagnostics’ patented Olo analyzer digitizes blood into images to perform the most common blood test in minutes, using just two drops of blood.
Read MoreThe Karius test detected bloodstream infections in 75% of cases as early as 3 days before pediatric leukemia patients became symptomatic.
Read MoreAI-driven digital pathology can accelerate cancer diagnosis and clinical trial recruitment.
Read MoreStrong concordance with standard-of-care methods shows how the Saphyr mapping system can transform cytogenetic workflows and improve blood cancer treatment.
Read MoreMonitoring cancer therapy in real time enables physicians to make smarter treatment decisions.
Read MoreThe funds will be used to accelerate commercialization of Saga’s portfolio of kits and services, continue development of new products, and perform prospective clinical studies.
Read MoreThe Aurora system is now available with five lasers, making it possible for researchers to visualize more than 30 colors from a single sample.
Read MoreThe study demonstrates the potential for more impactful, dynamic therapy development and applications for those with acute myeloid leukemia.
Read MoreThe license encompasses both a novel method and bioinformatic tools that combine to improve the level of detection in NGS, allowing for the identification of ultrarare gene variants.
Read MoreUsing the kit, clinicians can accurately and reproducibly monitor residual disease in patients with chronic myeloid leukemia, even at low levels.
Read MoreClearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burden.
Read MoreDroplet digital PCR can provide a more accurate assessment of low levels of BCR-ABL mRNA than quantitative real-time PCR.
Read More